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Abstract  Management  of  patients  with  a  benign  hepatocellular  tumor  relies  largely  on  imaging
data; the  diagnosis  of  focal  nodular  hyperplasia  (FNH)  must  be  made  with  certainty  using  MRI,
because  no  other  clinical  or  laboratory  data  can  help  diagnosis.  It  is  also  essential  to  identify
adenomas  to  manage  them  appropriately.  The  radiological  report  in  these  situations  is  thereforeFocal  nodular
hyperplasia
of major  importance.  However,  there  are  diagnostic  traps.  The  aim  of  this  paper  is  to  present
the keys  to  the  diagnosis  of  benign  lesions  and  to  warn  of  the  main  diagnostic  pitfalls.
© 2013  Published  by  Elsevier  Masson  SAS  on  behalf  of  the  Éditions  françaises  de  radiologie.
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wBenign  hepatocellular  tumors  are  rare,  making  up  10%  of
benign  hepatic  tumors  [1—3].  Two  large  groups  of  benign
hepatocellular  tumors  can  be  differentiated:  reactive  regen-
erative  lesions  —  focal  nodular  hyperplasia  (FNH),  and
tumoral  lesions  —  hepatocellular  adenomas.  The  common
feature  of  these  two  groups  of  lesions  is  that  they  develop
most  often  in  young  women  [1—3].
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http://dx.doi.org/10.1016/j.diii.2013.05.002It  is  essential  to  use  imaging  to  diagnose  these  lesions
n  order  to  decide  how  to  manage  the  situation.  This  can
ange  from  no  therapeutic  treatment  to  surgical  resection,
ith  monitoring  or  a  biopsy  for  conﬁrmation  as  inter-
ediate  stages  [1—3].  In  recent  years,  identiﬁcation  of
olecular  alterations  within  benign  hepatocellular  tumoral
esions  has  provided  better  understanding  of  the  patho-
hysiology  and  genesis  of  the  tumor  [4].  Correlation  of  the
enotypic  and  phenotypic  data  of  hepatocellular  adenomas
eems  to  be  important  for  determining  their  management
5]. While  diagnosis  and  management  of  these  lesions  is
 on behalf of the Éditions françaises de radiologie.
6m
g
r
i
u
n
m
i
M
t
i
t
T
h
F
M
T
(
M
e
e
e
l
i
f
•
•
•
•
•
n
s
t
F
a
L
c
D
[
c
b
f
a
r
c
c
o
o
p
c
2
t
b
m
o
e
t
l
t
a
d
t
9
c
w
h
h
F
F
u
U
s
l
t
u
e
o
t
p
i
T
b
i
s
u
i
9
s
T
H
O
a
H
t78  
ultidisciplinary  —  involving  clinicians,  hepatologists,  sur-
eons  and  histopathologists  along  with  radiologists  —  the
adiologist  is  in  the  front  line  for  studying  their  signs.
MRI  is  nowadays  the  reference  examination  for  character-
zing  benign  hepatocellular  tumors  [6],  sometimes  with  the
se  of  liver-speciﬁc  contrast  agents  [7].  Nevertheless,  all  is
ot  simple:  atypical  forms  or  particular  terrains  may  still
ake  diagnosis  of  FNH  difﬁcult.  Adenomas  are  now  classed
n  pathomolecular  subtypes,  depending  particularly  on  their
RI  proﬁle  [8].
The  aim  of  this  paper  is  to  provide  an  overview  of  the
ypical  presentation  of  benign  hepatocellular  lesions,  before
llustrating  the  atypical  forms  or  the  most  common  diagnos-
ic  traps.
ypical presentations of benign
epatocellular lesions — an overview
ocal nodular hyperplasia (FNH)
RI
ypical  MRI  appearance  of  focal  nodular  hyperplasia
FNH) after  injection  of  gadolinium  chelates
RI  diagnostic  criteria  for  FNH  were  proposed  by  Mattison
t  al.  based  on  the  analysis  of  six  criteria  on  non-contrast
nhanced  MRI  sequences  [9],  then  improved  by  Mathieu
t  al.  with  the  study  of  the  contrast  uptake  kinetics  of  these
esions  after  dynamic  injection  of  gadolinium  chelates  [10].
The  MRI  pathognomonic  features  of  typical  FNH  follow-
ng  injection  of  conventional  gadolinium  chelates  are  the
ollowing  ﬁve  characteristic  signs:
T1-weighted  isointensity  or  discreet  hypointensity,  asso-
ciated  with  T2-weighted  isointensity  or  discreet  hyperin-
tensity;
the  presence  of  a  T2-weighted  hyperintense  central  stel-
late  scar;
homogeneity  outside  of  the  central  stellate  scar;
intense  homogeneous  arterial  uptake  of  contrast,  the
lesion  returning  to  isointensity  with  the  liver  in  the  portal
and  late  phases;
the  absence  of  a  capsule.
The  majority  of  studies  show  that  MRI  has  a  high  diag-
ostic  value  for  FNH,  with  sensitivity  of  about  80%  and
peciﬁcity  of  98%  [1,11].  Fig.  1  (a—e)  shows  an  example  of
ypical  FNH  in  MRI.
ocal  nodular  hyperplasia  and  liver-speciﬁc  contrast
gents:  do  they  provide  additional  speciﬁc  help?
iver-speciﬁc  contrast  agents  (the  liver-speciﬁc  gadolinium
helates  Gd-BOPTA,  Multihance®,  Bracco,  Italy  or  GD-EOB-
TPA,  Primovist®,  Bayer  Schering)  are  excreted  in  the  bile
12].  The  liver-speciﬁc  contrast  agent  enters  the  hepato-
ytes  via  a  transporter  in  their  sinusoidal  membrane  which
elongs  to  the  organic  anion  transporting  peptide  (OATP)
amily.  The  contrast  agent  is  excreted  into  the  bile  by  a  hep-
tocyte  canalicular  membrane  transporter,  the  multidrug
esistance-associated  protein  2  (MRP2).  The  liver-speciﬁc
ontrast  agents  accumulate  in  the  FNH  due  to  the  lack  of
ommunication  of  the  intratumoral  bile  ducts  with  the  rest
f  the  biliary  tree.  The  FNH  therefore  appears  hyperintense
c
b
T
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r  isointense  relative  to  the  adjacent  liver  in  the  hepatocyte
hase,  from  one  hour  after  injection  of  the  liver-speciﬁc
ontrast  agent  in  the  case  of  Gd-BOPTA,  or  from  about
0  minutes  after  injection  of  Gd-EOB-DTPA  [13].
There  have  been  several  studies  concerning  the  contribu-
ion  made  by  liver-speciﬁc  contrast  agents  to  characterize
enign  hepatocellular  tumors.  Grazioli  et  al.  found  enhance-
ent  of  FNH  in  96.3%  of  cases  three  hours  after  injection
f  Gd-BOPTA  whereas  none  of  the  adenomas  showed  any
nhancement  [7].  A  recent  study  using  Gd-EOB-DTPA  showed
hat  contrast  between  the  FNH  lesion  and  the  adjacent
iver  was  slightly  positive,  whereas  it  was  strongly  nega-
ive  for  adenomas.  The  ratio  of  the  signal  from  the  lesion
nd  the  adjacent  liver  in  the  hepatocyte  phase  allowing
ifferentiation  between  the  two  types  of  hepatocellular
umor  was  0.97,  with  sensitivity  of  92%  and  speciﬁcity  of
1%  [14].  Another  study  has  shown  that  reading  the  hepato-
yte  phase  increased  the  diagnostic  sensitivity  for  FNH:  FNH
as  correctly  diagnosed  in  74.3  to  97.1%  of  cases  before  the
epatocyte  phase  and  in  97.1%  to  100%  after  reading  the
epatocyte  phase  [15].
An  example  of  typical  FNH  using  Gd-BOPTA  is  shown  in
ig.  1  (f  and  g).
NH  and  ultrasonography  with  injection  of  an
ltrasound contrast  agent
sing  ultrasonography  with  intravenous  injection  of  an  ultra-
ound  contrast  agent,  the  central  artery  penetrating  the
esion  can  be  visualized  in  real  time:  there  is  early  cen-
rifugal  spoke-wheel  contrast  uptake  by  the  FNH,  before
ptake  by  the  normal  parenchyma.  The  lesion  is  completely
nhanced,  outside  of  the  central  stellate  scar,  at  the  end
f  the  arterial  phase,  and  becomes  hyperechoic  relative  to
he  adjacent  hepatic  parenchyma.  In  the  portal  and  late
hases  (60  seconds  to  3  minutes),  discreet  hyperechogenic-
ty  or  isoechogenicity  of  the  lesion  persists  in  most  cases.
he  central  stellate  scar  is  not  enhanced  in  the  late  phase
ut  remains  hypoechoic  in  all  phases  due  to  the  strictly
ntravascular  character  of  the  contrast  agent  used  in  ultra-
ound  [16,17].
In the  literature,  the  sensitivity  of  contrast  enhanced
ltrasound  for  diagnosis  of  FNH  varies  depending  on  the  stud-
es  between  80  and  100%,  with  speciﬁcity  of  between  85  and
5%  [18,19].
An  example  of  typical  FNH  using  contrast  enhanced  ultra-
ound  is  shown  in  Fig.  2.
Note  that  the  typical  criteria  for  FNH  are  summarized  in
able  1.
epatocellular adenomas
verview  of  the  molecular  classiﬁcation  of
denomas
epatocellular  adenomas  are  a  heterogeneous  group  of
umors,  with  their  potential  to  evolve  into  hepatocellular
arcinomas  (HCC)  and  the  risk  of  hemorrhagic  complications
eing  closely  linked  to  their  molecular  characteristics  [20].
here  are  four  recognized  molecular  types  of  adenoma
5,20,21]:
Imaging  benign  hepatocellular  tumors:  Atypical  forms  and  diagnostic  traps  679
Figure 1. Typical focal nodular hyperplasia. A 30-year-old woman with no noteworthy history. Chance discovery of a hepatic nodule of
the right liver. MRI characterization: a: the nodule is isointense with in-phase T1-weighted 2D GE; b: no decline in intensity with opposed-
phase T1-weighted 2D GE; c: the nodule is isointense with T2-weighted FSE FS, with a central stellate scar appearing hyperintense with
T2-weighting; d: the nodule takes up contrast intensely and uniformly in the arterial phase with T1-weighted 3D GE after injection of
gadolinium chelates; e: the nodule is isointense relative to the adjacent liver in the venous phase and shows contrast uptake by the central
scar; f and g: in the hepatocyte phase, after injection of a liver-speciﬁc contrast agent, the nodule is isointense with the adjacent liver with
in-phase (f) and with opposed-phase (g) T1-weighted 2D GE. Note that the central stellate scar appears hypointense with T1-weighting in
•the hepatocyte phase.
• adenomas  with  HNF1 mutations  (35—45%),  character-
ized  by  their  marked  steatosis  and  their  benign  evolution,
resulting  in  a  conservative  approach;
• adenomas  with    catenin  mutations  (15—20%)  charac-
terized  by  their  proportionally  greater  frequency  of
occurrence  in  men  and  their  high  risk  of  transformation
into  HCC  (30—40%);telangiectatic  or  inﬂammatory  adenomas  (35—40%),  char-
acterized  by  their  occurring  preferentially  in  obese
patients  or  in  patients  with  metabolic  syndrome  or  steato-
hepatitis.  These  adenomas  have  a  higher  hemorrhagic  risk
when  they  are  more  than  5-cm  in  size  [3].  An  associated
mutation  of  the    catenin  gene  can  exist  in  about  10%  of
this  adenoma  subtype,  with  a  risk  of  evolving  into  HCC;
680  L.  Baranes  et  al.
Figure 2. Focal nodular hyperplasia (FNH) with contrast enhanced ultrasound. A 27-year-old woman. Nodule at the junction of segments
VI and VII suggesting focal nodular hyperplasia. Contrast enhanced ultrasound found centrifugal contrast uptake typical of FNH (a—g).
Imaging  benign  hepatocellular  tumors:  Atypical  forms  and  diagnostic  traps  681
Table  1  Criteria  of  typical  focal  nodular  hyperplasia  (FNH)  (Figs.  1  and  2).
MRI  Contrast  enhanced  ultrasound
Without  injection  T1-weighted  isointensity  or
discreet  hypointensity
T2-weighted  isointensity  or
discreet  hyperintensity
Homogeneity  outside  of  the  central
stellate  scar
Central  stellate  scar  with
T2-weighted  hyperintensity
Early,  arterial,  centrifugal,
spoke-wheel  contrast  uptake
Nodule  hyperechoic  at  the  end  of
the  arterial  phase
Nodule  iso-  or  discreetly
hyperechoic  in  the  portal  and  late
phases
Injection  of  gadolinium  chelates  Intense  uniform  arterial  contrast
uptake
Nodule  isointense  with  the  liver  in
the  portal  and  late  phases
Late  contrast  uptake  by  the  central
stellate  scar
Analysis  in  the  hepatocyte  phase  (only
for  liver-speciﬁc  gadolinium  contrast
agents)
Nodule  is  iso-  or  hyperintense
relative  to  the  adjacent  liver
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o• non-speciﬁc  adenomas  (10—20%),  with  no  molecular  or
phenotypic  characteristic  known  to  date.
MRI
The  MRI  signs  of  adenomas  appear  to  be  partly  correlated
with  their  genotype,  at  least  as  far  as  HNF1 mutation  and
inﬂammatory  adenomas  are  concerned  [8]:
• telangiectatic  or  inﬂammatory  adenomas  show  T1-
weighted  iso-  or  hyperintensity,  clear  T2-weighted
hyperintensity,  arterial  phase  contrast  uptake,  and  hyper-
intensity  relative  to  the  adjacent  liver  on  later  sequences.
Areas  of  steatosis  or  intratumoral  hemorrhagic  changes
are  possible.  In  the  study  by  Laumonier  et  al.  [8], the
association  of  ‘obvious  T2-weighted  hyperintensity’,  i.e.
at  least  equal  to  that  of  the  spleen,  and  ‘persistent
enhancement  in  the  portal  and  late  phase  sequences’  had
a  positive  predictive  value  of  88.5%,  a  negative  predictive
value  of  84%,  sensitivity  of  85.2%  and  speciﬁcity  of  87.5%
for  the  molecular  diagnosis  of  inﬂammatory  adenomas
(Fig.  3);
• steatotic  adenomas  suspected  of  being  an  HNF1
mutation  show  T2-weighted  isointensity  or  discreet
hyperintensity,  with  a  clear,  uniform  and  overall  fall
in  intensity  between  the  in-phase  and  opposed-phase
sequences,  corresponding  to  an  increase  in  fat  occupying
the  majority  of  the  lesion.  There  is  moderate  enhance-
ment  in  the  arterial  phase,  with  iso-  or  hypointensity
relative  to  the  adjacent  liver  on  later  sequences.  Accord-
ing  to  the  study  by  Laumonier  et  al.  [8],  the  ‘uniform
and  overall  fall  in  intensity  between  the  in-phase  and
opposed-phase  sequences’  has  a  positive  predictive  value
of  100%,  negative  predictive  value  of  94.7%,  sensitivity  of
86.7%  and  speciﬁcity  of  100%  for  the  molecular  diagnosis
of  HNF1 mutated  adenomas  (Fig.  4);
• the    catenin  mutated  subtype  of  adenoma  cannot  at
present  be  characterized  by  imaging.
t
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oepatocellular  adenomas  and  ultrasonography
fter  injection  of contrast  agent
n  contrast  enhanced  ultrasound,  the  enhancement  kinet-
cs  of  adenomas  is  not  speciﬁc:  it  may  be  centripetal
r  mixed  [22].  A  recent  study  tried  to  document  the
ontrast-enhanced  sonographic  features  speciﬁc  for  ade-
oma  subtypes.  HNF1-inactivated  adenomas  was  found
o  have  a  homogeneous  hyperechoic  aspect  at  baseline
ray-scale  sonography,  isovascularity  or  moderate  hyper-
ascularity  with  mixed  ﬁlling  in  the  arterial  phase,  and
soechogenicity  in  the  portal  and  late  portal  venous  phases.
nﬂammatory  adenomas,  was  found  to  have  an  arterial
ypervascularity  with  centripetal  ﬁlling,  linear  vasculari-
ies,  peripheral  rim  of  sustained  enhancement,  and  central
ashout  in  the  late  venous  phase  [23].
Note  that  the  criteria  indicating  an  adenoma  are  summa-
ized  in  Table  2.
typical forms and diagnostic traps
hile  the  typical  forms  of  FNH  are  easy  to  recognize  in  MRI,
ertain  forms  are  difﬁcult  to  diagnose  and  particularly  to  dif-
erentiate  from  an  adenoma.  Nevertheless,  certain  classic
raps  can  be  avoided.
oes FNH occur in men?
t  is  generally  agreed  that  FNH  is  much  less  common  in  men
han  in  women.  The  male/female  ratio  for  the  occurrence  of
his  lesion  is  1  to  8  [24]. FNH  lesions  in  men  are  smaller,  more
ften  atypical  in  MRI  and  age  at  diagnosis  is  generally  higher
han  in  women  [25].  Considerable  caution  will  therefore
e  used  in  diagnosing  FNH  in  men  from  imaging,  adhering
trictly  to  the  MRI  criteria  for  this  non-invasive  diagnosis.  If
ne  of  these  criteria  is  absent,  it  is  recommended  to  seek  an
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Figure 3. Inﬂammatory adenoma with MRI. A 36-year-old overweight woman. Chance discovery of a subcapsular nodule of segment VI: a:
this nodule is hypointense with in-phase T1-weighted 2G GE; b: the steatotic liver shows a fall in intensity with opposed-phase T1-weighted
2D GE; c: the nodule is clearly hyperintense in the T2 FSE FS sequence; d and e: after injecting gadolinium chelates, the nodule takes up
the contrast intensely and heterogeneous in the arterial phase (d), with hyperintensity persisting in the venous phase (e); f and g: in the
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depatocyte phase after injecting Gd-BOPTA, the nodule is hypointe
g) T1-weighted 2D GE sequences. The diagnosis of an inﬂammator
pinion  from  a  specialized  center,  and  a  percutaneous  biopsy
hould  be  performed  where  there  is  the  slightest  doubt.
o multiple FNH exist?
bout  20%  of  patients  present  at  least  two  FNH  lesions  [24].
t  is  therefore  quite  usual  to  ﬁnd  several  FNH  nodules  in  a sin-
le  patient.  A  classic  differential  diagnosis  is  nodular  regen-
rative  hyperplasia  (NRH)  in  its  multi-acinar  pseudotumoral
orm  which  can  mimic  FNH  (Fig.  5)  in  patients  with  a  particu-
s
h
t
[lative to the adjacent liver on the in-phase (f) and opposed-phase
noma was conﬁrmed by histopathology.
ar  clinical  context:  systemic  diseases  (rheumatoid  arthritis,
clerosis,  lupus),  hematological  diseases,  certain  medic-
nal  products  (azathioprine,  6-thioguanine,  chemother-
py  —  in  particular  oxaliplatin),  congenital  hepatic  vascular
bnormalities,  hepatic  or  renal  transplant,  HIV,  car-
iac  insufﬁciency,  coeliac  disease,  chronic  Budd—Chiari
yndrome.  Classically,  NRH  takes  up  contrast  in  the
epatocyte  phase  after  injection  of  liver-speciﬁc  con-
rast  agent  and  does  not  have  a  central  stellate  scar
26,27].
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Figure 4. Steatotic adenoma with an HNF1 mutation in MRI. Chance discovery of a mass at the junction of segments V and VI in a
29-year-old woman with no noteworthy history: a: the nodule is isointense on the in-phase T1-weighted 2D GE sequence; b: there is an
overall, uniform fall in intensity in the opposed-phase T1-weighted 2D GE sequence; c: the nodule is isointense with T2-weighted FSE FS; d
and e: it is weakly enhanced in the arterial phase after injection of gadolinium chelates (d) and remains hypointense relative to the liver
in the venous phase (e); f: in the hepatocyte phase, the nodule is hypointense relative to the adjacent liver with in-phase T1-weighted 2D
GE. The diagnosis of steatotic adenoma with an HNF1 mutation was conﬁrmed on the resected tissue.
Table  2  Characteristic  signs  of  hepatocellular  adenomas.
MRI  Contrast  enhanced  ultrasound
Inﬂammatory  adenoma
(Fig.  2)
T2-weighted  hyperintensity  at  least
equal  to  that  of  the  spleen
Hypervascular  in  the  arterial  phase
Nodule  hyperintense  relative  to  the
liver  in  the  venous  phase
Inﬂammatory  adenoma:  arterial  hypervascularity
with  centripetal  ﬁlling,  linear  vascularities,
peripheral  rim  of  sustained  enhancement,  and
central  washout  in  the  late  venous  phase
Steatotic  adenoma:  homogeneous  hyperechoic
aspect  at  baseline  gray-scale  sonography,
isovascularity  or  moderate  hypervascularity  with
mixed  ﬁlling  in  the  arterial  phase,  and
isoechogenicity  in  the  portal  and  late  portal
venous  phases
Steatotic  adenoma
(Fig.  3)
Overall,  uniform  fall  in  intensity  in
opposed-phase  T1-weighting
Iso-  or  discreet  hyperintensity  with
T2-weighting
Slightly  hypervascular  in  the  arterial
phase
684  L.  Baranes  et  al.
Figure 5. Nodular regenerative hyperplasia. A 69-year-old male patient with a history of cancer of the colon (T3N + M0), treated by
adjuvant chemotherapy with biological therapy, in complete clinical/laboratory test remission. Appearance of hepatic nodules during CT
monitoring: a: the T1-weighted 3D GE FS sequence before injection shows hypointense lesions, particularly subcapsular in the anterior part
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if the left lobe (arrow); b: in the hepatocyte phase after injecting G
 sign suggesting their hepatocytic character. Biopsy of one of thes
re all hypervascular lesions hepatocellular?
rterial  contrast  uptake  by  a  nodule  is  not  speciﬁc  for  its
eing  hepatocellular.  The  range  of  hypervascular  hepatic
esions  does  indeed  include  the  hepatocellular  tumors  (ade-
oma,  FNH,  HCC),  but  also  vascular  lesions  (perfusion
isorders,  angioma),  as  well  as  metastases  of  hypervascu-
ar  tumors  (medullary  thyroid  carcinoma,  neuro-endocrine
umor  of  the  kidney,  sarcoma,  melanoma)  (Fig.  6),  which
ay  mean  that  differential  diagnosis  is  difﬁcult.
oes the presence of fat exclude the diagnosis
f FNH?
atty  transformation  of  FNH  is  rare  [28].  In  a  study  in  2004,
5%  of  FNH  classiﬁed  as  atypical  presented  intralesional  fat
29].  It  has  been  suggested  that  subjacent  hepatic  steato-
is  might  extend  into  FNH  [30].  When  fatty  transformation
s  the  only  atypical  feature  and  particularly  when  the  sub-
acent  liver  is  steatotic,  hyperintensity  in  the  T1-weighted
equences  due  to  the  presence  of  fat  within  the  FNH  should
ot  bring  the  diagnosis  into  question.  In  other  cases,  the
resence  of  fat  modiﬁes  the  characteristics  of  the  signal
rom  the  lesion  relative  to  the  subjacent  liver  making  differ-
ntial  diagnosis  with  an  adenoma  difﬁcult,  so  that  diagnosis
f  FNH  may  require  the  assistance  of  liver-speciﬁc  contrast
gents  or  a  percutaneous  biopsy  (Fig.  7).
s the presence of a central stellate scar
ynonymous with FNH?
his  is  a  complex  question.  We  must  ﬁrst  separate  the  issues.
oes  the  absence  of  a  central  stellate  scar  exclude
iagnosis of  FNH?
he  central  stellate  scar  with  T2-weighted  hyperintensity,
nhancing  in  the  venous  phase,  is  among  the  MRI  diagnos-
ic  criteria  for  FNH.  However,  in  many  cases,  this  central
tellate  scar  is  not  formally  visualized  in  MRI.  It  is  now
cknowledged  that  it  may  not  be  seen  in  small  FNH  lesions,
l
m
l
bPTA, these nodules have taken up contrast at the periphery (arrow),
ules provided the diagnosis of nodular regenerative hyperplasia.
.e.  those  of  largest  diameter  of  less  than  3-cm  [11,24].  If
ll  the  other  diagnostic  criteria  are  present  and  there  is
o  particular  medical  history,  the  diagnosis  of  FNH  may  be
ade  even  if  there  is  no  central  stellate  scar  in  lesions  of
ess  than  3-cm.  Here  again,  contrast  enhanced  ultrasound
ay  be  useful  because  it  is  more  sensitive  for  detecting  the
entral  stellate  scar  [31]. An  MRI  with  injection  of  a  liver-
peciﬁc  contrast  agent  and  studying  the  hepatocyte  phase
ay  otherwise  provide  an  additional  diagnostic  argument.
oes  the  presence  of  a  central  stellate  scar
onﬁrm diagnosis  of  FNH?
2-weighted  hyperintensity  of  the  central  stellate  scar  and
ontrast  uptake  in  the  venous  phase  are  essential  for  diag-
osis  of  FNH.  T2-weighted  hypointensity  of  the  central
tellate  scar  is  in  fact  very  unusual  and  requires  additional
nvestigation  in  order  to  eliminate  diagnosis  of  ﬁbrolamel-
ar  hepatocellular  carcinoma,  in  particular.  On  the  other
and,  the  central  artery,  which  can  sometimes  be  seen  in
2-weighted  hypointensity,  must  not  be  confused  with  a  T2-
eighted  hypointense  central  stellate  scar  (Fig.  8).  In  MRI,
t  can  sometimes  be  useful  to  wait  for  several  minutes  after
njecting  the  contrast  agent  to  identify  enhancement  of  the
entral  stellate  scar.  Moreover,  certain,  in  particular  inﬂam-
atory,  adenomas  may  also  present  a  central  stellate  scar
Fig.  9).
oes a mixed or centripetal ﬂow in contrast
nhanced ultrasound exclude the diagnosis of
NH?
hen  there  is  centripetal  or  mixed  ﬂow  in  contrast  enhanced
ltrasound,  the  ﬁrst  reﬂex  should  be  to  ensure  that  the  plane
f  the  slice  is  satisfactory,  i.e.  that  it  passes  through  the  sup-
lying  pedicle,  because  a  poor  slice  plane  may  result  in  false
mages  of  mixed  or  centripetal  enhancement.  FNH,  when
arge,  may  however  have  several  supplying  pedicles.  This
ay  cause  contrast  enhanced  ultrasound  results  for  these
arge  lesions,  typically  of  more  than  5-cm,  to  be  atypical
y  showing  mixed  or  even  centripetal  ﬂow  (Fig.  10).  This
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Figure 6. Renal carcinoma metastasis. A 52-year-old female patient; discovery of a hypervascular hepatic nodule on a CT scan performed
during staging of a renal carcinoma; MRI characterization: a and b: the nodule (arrow) is hypointense on the in-phase (a) and opposed-phase
(b) T1-weighted GE sequences; c: it is clearly hyperintense on the T2-weighted FSE FS sequences; d: arterial contrast uptake after injection
 liver
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bof gadolinium chelates; e: the nodule is hypointense relative to the
appearance  does  not  exclude  the  diagnosis  of  FNH  for  large
lesions,  for  which  MRI  should  be  preferred.
How should the hepatocyte phase be
interpreted after injection of a liver-speciﬁc
contrast agent?In  the  hepatocyte  phase,  an  FNH  is  typically  isointense  or
hyperintense  relative  to  the  adjacent  liver  after  injecting
a  liver-speciﬁc  contrast  agent,  on  in-phase  or  opposed-
phase  T1-weighted  2D  gradient-echo  (GE)  sequences  and
m
i
u
ﬁ in the venous phase. It was metastasis of a renal carcinoma.
n  T1-weighted  3D  GE  sequences  with  fat  saturation.
ecause  of  its  better  spatial  resolution,  the  T1-weighted
D  GE  sequence  with  fat  saturation  loses  contrast  resolu-
ion,  and  contrast  uptake  by  the  lesion  may  appear  less
ntense  than  on  a  T1-weighted  2D  GE  sequence.  In  addi-
ion,  the  signal  from  the  lesion  in  the  hepatocyte  phase
s  assessed  relative  to  the  adjacent  liver,  itself  inﬂuenced
y  instrumental  parameters  such  as  TE  and  ﬂip  angle.  It
ay  therefore  be  important  to  perform  several  sequences
n  the  hepatocyte  phase,  to  avoid  missing  any  contrast
ptake  by  the  lesion.  It  should  be  noted  that  in  the
rst  study  by  Grazioli  et  al.  [7],  study  of  the  hepatocyte
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Figure 7. Focal nodular hyperplasia (FNH) containing fat. A 48-year-old female patient, with no noteworthy history. Chance discovery of
a hepatic dome lesion. MRI characterization: a: the nodule (arrow) is hyperintense on the in-phase T1-weighted 2D GE sequence; b: the
fall in intensity in the opposed-phase T1-weighted 2D GE sequence is evidence of its fat component; c: the lesion is hyperintense in the
T2-weighted FSE FS sequence, with a hyperintense central stellate scar with T2-weighting; d and e: the nodule is intensely enhanced in the
arterial phase (d) after injecting Gd-BOPTA and becomes isointense with the adjacent liver in the venous phase, with contrast uptake by
the central part (e); f and g: in the hepatocyte phase, the nodule is hyperintense relative to the adjacent liver in the in-phase T1-weighted
2D GE sequences (f) but above all with opposed-phase T1-weighted 2D GE (g), evidence of the capture of the liver-speciﬁc contrast agent
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aavoring diagnosis of FNH.
hase  only  concerned  the  T1-weighted  2D  gradient-echo
equences.
Moreover,  certain  FNH  only  took  up  contrast  at  the
eriphery,  in  a  ring  (Fig.  11),  in  the  hepatocyte  phase,  with  a
enter  remaining  hypointense  relative  to  the  adjacent  liver
32].  This  appearance  should  not  call  the  diagnosis  into  ques-
ion.
C
w
cn MRI, is contrast uptake in the hepatocyte
hase after injecting a liver-speciﬁc contrast
gent synonymous with FNH?ertain  forms  of  hepatocellular  carcinoma  may  be  isointense
ith  or  hyperintense  to  the  adjacent  liver  in  the  hepato-
yte  phase  [33—35]. Contrast  uptake  by  a  nodule  in  the
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Figure 8. Central artery simulating a hypointense scar in a 35-year-old female patient with a typical focal nodular hyperplasia (FNH)
seen in imaging: a: on the T2-weighted FSE sequence, the central artery appears hypointense (arrow head), while the central stellate scar
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3appears hyperintense (arrow); b: in the arterial phase, the central a
hypointense (arrow); c: In the venous phase series, the central stel
hepatocyte  phase  does  not  therefore  mean  that  FNH  can
be  diagnosed.  It  is  essential  to  analyze  the  terrain,  the  mor-
phology  of  the  liver  and  the  characteristics  of  the  nodule
with  no  contrast  enhancement  as  well  as  during  the  dynamic
phases  after  contrast  injection,  before  diagnosing  FNH.
Can an adenoma be formally diagnosed by
non-invasive means?
In  practice,  this  question  only  applies  to  steatotic  ade-
nomas  suspected  of  being  HNF1 mutations,  since  all  the
other  lesions  suspected  of  being  adenomas  must  have  at
least  one  hepatic  biopsy  to  look  for  the    catenin  mutation,
the  risk  factor  for  evolution  into  hepatocellular  carcinoma.
The  correlation  between  MRI  and  the  histopathologic  and
immunohistochemical  diagnosis  of  the  adenoma  subtype  is
excellent  for  steatotic  and  inﬂammatory  adenomas,  but
to  date  has  only  been  studied  in  a  population  of  adeno-
mas  [8,36].  As  regards  steatotic  adenomas  suspected  of
being  HNF1 mutations,  the  differential  diagnosis  with  a
hepatocellular  carcinoma  is  based  only  on  the  background
of  chronic  liver  disease  and  arterial  contrast  uptake  by
the  HCC,  because  the  uniform  overall  fall  in  intensity
in  opposed-phase  T1-weighting,  very  speciﬁc  for  HNF1
mutated  steatotic  adenomas  in  a  population  of  adenomas,
may  perfectly  well  be  encountered  in  HCC,  all  the  more  so
when  they  are  small  [28].  This  must  lead  to  caution  and  close
monitoring  of  adenomas  labeled  as  steatotic  and  suspected
of  being  HNF1 mutations  without  any  histopathologic  and
immunohistochemical  evidence.
Can liver overload be a source of diagnostic
traps?
A  steatotic  liver  may  alter  the  ratio  of  the  signal  between
the  liver  and  the  lesion.  For  this  reason  it  is  preferable  to
study  the  enhancement  of  a  lesion  in  the  hepatocyte  phase
on  a  sequence  in  which  the  lesion  is  hypo  or  isointense  rel-
ative  to  the  adjacent  liver  before  injection  —  in  practice,
often  the  in-phase  T1-weighted  2D  GE  sequence  —  in  order
to  appreciate  the  behavior  of  the  lesion  better  (Fig.  12). is enhanced (arrow head), while the central stellate scar remains
car is enhanced (arrow).
Hepatic  iron  overload  also  leads  to  modiﬁcations  of
he  ratio  of  the  signal  between  the  liver  and  the  lesion.
ron  overload  causes  an  increase  in  liver  intensity  on  the
pposed-phase  T1-weighted  2D  GE  sequence  compared  with
he  in-phase  T1-weighted  2D  GE  sequence.  Moreover,  a
esion  appears  more  obviously  hyperintense  compared  with
he  adjacent  liver  in  the  T2-weighted  sequence,  making
iagnosis  of  FNH  more  difﬁcult.
n practice, how do we cope with this?
he  diagnosis  of  benign  hepatocyte  lesions  is  based  essen-
ially  on  analysis  of  MR  images.  Trap  situations  and  atypical
orms  of  these  lesions  are  now  well  known.  Ultrasonography
ith  the  injection  of  a  contrast  agent  and  the  use  of  liver-
peciﬁc  MRI  contrast  agents  could  ultimately  strengthen  the
iagnostic  arsenal  for  these  lesions  further.  A  proposal  for  a
anagement  algorithm  is  shown  in  Inset  1.
linical case
his  55-year-old  male  patient  had  a  liver  transplant  3  months
go  for  alcoholic  cirrhosis  complicated  by  hepatocellular
arcinoma  nodules.  He  had  a  hepatic  MRI  during  system-
tic  monitoring  because  of  the  high  risk  of  recurrence  of  his
isease.  His  liver  function  tests  are  normal,  as  is  his  blood
lpha-fetoprotein  level.  This  is  his  MRI,  which  shows  a  single,
ne  centimeter,  hepatic  nodule  (Fig.  13  a—f).
uestions
.  Describe  the  images.  What  are  your  diagnostic  hypothe-
ses?  Give  your  reasons.
.  How  can  diagnostic  progress  be  made  using  imaging?
.  An  additional  MRI  with  injection  of  a  liver-speciﬁc  con-
trast  agent  (Fig.  13  g  and  h)  and  a  contrast  enhanced
ultrasound  examination  (Fig.  14)  were  performed.  How
do  you  interpret  them?  Can-you  suggest  a  diagnosis  or
suitable  management?
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Figure 9. Inﬂammatory adenoma with a stellate scar. A 24-year-old female patient, with no noteworthy history. Chance discovery of a
mass in segment VI. MRI characterization: a and b: the nodule is isointense in the in-phase and opposed-phase T1-weighted 2D GE sequences;
c: it is discreetly hyperintense in the T2-weighted FSE FS sequence, with a central stellate scar with T2-weighted hyperintensity; d and e:
the nodule is intensely, heterogeneously enhanced in the arterial phase after injecting Gd-BOPTA (d), with discreet hyperintensity relative to
the adjacent liver in the venous phase (e). Note that the central stellate scar is not enhanced in the venous phase; f and g: in the hepatocyte
phase the nodule is hypointense relative to the adjacent liver on the in-phase (f) and opposed-phase (g) T1-weighted 2D GE sequences. This
a The d
A
1ppearance is not indicative of an focal nodular hyperplasia (FNH). 
nswers
.  This  is  a  steatotic  hepatic  graft  (Fig.  13a  and  b).  The
one  centimeter,  subcapsular  nodule  is  hypointense  on
in-phase  T1-weighted  sequences  (Fig.  13a)  and  hyperin-
tense  with  T2-weighted  FS  (Fig.  13c).  It  takes  up  contrast
intensely  and  uniformly  in  the  arterial  phase  (Fig.  13d),
with  discreet  hyperintensity  relative  to  the  adjacentiagnosis of an inﬂammatory adenoma was conﬁrmed histologically.
liver  in  the  portal  and  venous  phases  (Fig.  13e  and  f).
There  is  no  central  stellate  scar.
With  this  hypervascular  nodule  the  possible  diagnoses
are:•  early  recurrence  of  hepatocellular  carcinoma  on
the  graft,  but  there  is  no  washout  in  the  portal
phase;  alpha-fetoprotein  is  normal  but  the  nodule  is
small;
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Figure 10. Focal nodular hyperplasia (FNH) with mixed ﬂow in a contrast enhanced ultrasound examination. Discovery of a 7-cm left lobe
mass in a 37-year-old woman, with no noteworthy history: a: ultrasonography in B mode showing the mass; b—f: contrast enhanced ultrasound
shows centripetal and centrifugal, mixed, dynamic ﬁlling of the mass, not allowing a differential diagnosis; g—i: the MRI which followed
shows the left lobe mass as T1-weighted hypointensity (g), T2-weighted discreet hyperintensity, with a central stellate scar hyperintense
with T2-weighting (h) and obvious arterial contrast uptake outside of the central stellate scar (i); j and k: in the hepatocyte phase after
injecting a liver-speciﬁc contrast agent a mass is seen isointense with the liver on the in-phase T1-weighted 2D GE sequence (j). The
diagnosis was therefore of FNH.
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rigure 10. ( Continued ).
•  a  nodule  of  focal  nodular  hyperplasia.  There  is  no  cen-
tral  stellate  scar,  but  the  nodule  is  less  than  3-cm.  The
marked  T2-weighted  hyperintensity  and  its  persistence
relative  to  the  liver  in  the  portal  and  venous  phases  may
be  explained  by  hepatic  steatosis;
•  an  adenoma,  of  the  inﬂammatory  type  because  of  its
hypervascular  character;
•  metastasis  of  a  primary  hypervascular  tumor;
•  a  perfusion  disorder  is  excluded  because  this  is  a  nod-
ule,  clearly  visible  on  the  morphological  sequences
igure 11. Focal nodular hyperplasia (FNH) after injecting a liver-spec
y histology: a: the nodule is hypointense with non-enhanced T1-weigh
ing, in the hepatocyte phase, after injecting Gd-BOPTA (arrow).without  injection.  Nor  is  it  an  angioma,  because  the
contrast  uptake  and  the  T2-weighted  signal  are  not
those  of  an  angioma.
.  Performing  an  MRI  with  injection  of  a  liver-speciﬁc  con-
trast  agent  might  help  characterize  the  nodule  better.
Contrast  uptake  in  the  hepatocyte  phase  will  speak  in
favor  of  a  hepatocellular  lesion,  without  making  it  pos-
sible  to  formally  exclude  a  hepatocellular  carcinoma.
With  a  contrast  enhanced  ultrasound  examination,  the
nodule  will  be  characterized  better,  depending  on  the
iﬁc contrast agent. A 45-year-old man. FNH of the right liver proven
ted 3D GE FS (arrow); b: it shows peripheral contrast uptake in a
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Figure 12. Focal nodular hyperplasia (FNH) on a steatotic liver. Overweight 45-year-old man. Discovery of a nodule of the right liver on a
steatotic liver. MRI characterization: a: the nodule appears hypointense in the in-phase T1-weighted 2D GE sequence; b: it is hyperintense
in opposed-phase T1-weighted 2D GE, due to the fall in signal from the steatotic liver; c: it is discreetly hyperintense in T2-weighted FSE
FS, with no evident central stellate scar; d and e: it takes up contrast intensely in the arterial phase (d), with discreet hyperintensity
persisting relative to the adjacent liver in the venous phase (e); f and g: in the hepatocyte phase, it is difﬁcult to study the nodule on the
opposed-phase T1-weighted 2D GE sequence (f), since it was already spontaneously hyperintense. The in-phase T1-weighted 2D GE sequence
 phas
gy.shows that the nodule is isointense with the liver in the hepatocyte
agent, which suggests FNH. This diagnosis was conﬁrmed by histolo
hepatopetal  or  hepatofugal  contrast  uptake  and  the
behavior  of  the  nodule  in  the  venous  phase.
3.  Contrast  uptake  by  the  nodule  on  the  MRI  in  the  hep-
atocyte  phase  can  only  be  analyzed  on  the  in-phase
T1-weighted  2D  GE  (Fig.  13g)  and  T1-weighted  3D  GE  FS
(Fig.  13i)  sequences, since  the  nodule  is  already  sponta-
neously  hyperintense  on  the  opposed-phase  T1-weighted
2D  GE  sequence  (Fig.  13b),  due  to  the  hepatic  steatosis. ne (g), and that it has therefore captured the liver-speciﬁc contrast
By  comparing  Fig.  13a,  g,  and  c  and  i,  respectively,  it  can
be  seen  that  this  nodule  takes  up  contrast  in  the  hepa-
tocyte  phase.  The  contrast  enhanced  ultrasound  shows
the  subcapsular  nodule  (Fig.  14a).  The  dynamic  contrast
uptake  is  centrifugal  (Fig.  14b—e).
In  all,  this  one  centimeter  nodule  is  compatible  with  diag-
osis  of  FNH.  Added  to  this  is  the  fact  that  the  liver  graft
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Figure 13. MRI: a: in-phase T1-weighted 2D GE sequence; b: opposed-phase T1-weighted 2D GE sequence; c: T2-weighted TSE sequence
with fat saturation; d: T1-weighted 3D GE sequence with fat saturation in the arterial phase; e: T1-weighted 3D GE sequence with fat
saturation in the portal phase; f: T1-weighted 3D GE sequence with fat saturation in the venous phase; g: in-phase T1-weighted 2D GE
sequence in the hepatocyte phase; h: opposed-phase T1-weighted 2D GE sequence in the hepatocyte phase; i: T1-weighted 3D GE sequence
with fat saturation in the hepatocyte phase.
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Figure 13. ( Continued ).
Figure 14. Contrast enhanced ultrasound: a: without injection of contrast agent; b—e: dynamic arrival of the contrast agent in the lesion.
694  
TAKE-HOME  MESSAGES
• MRI  is  the  gold  standard  for  characterizing  benign
hepatocellular  tumors.  There  is  a  place  for  contrast
enhanced  ultrasound  in  diagnosing  FNH  <  5-cm,  with
typical  centrifugal  enhancement.
• The  MRI  criteria  for  typical  FNH  are  well  known.
Nevertheless,  the  presence  of  intralesional  fat  and
the  absence  of  a  central  stellate  scar  for  lesions
of  less  than  3-cm  should  not  call  the  diagnosis  into
question.
• Certain  molecular  subtypes  of  adenomas,  HNF1
mutations  and  inﬂammatory  adenomas  may  be
suspected  from  their  MRI  proﬁle.
• When  diagnosis  is  difﬁcult  between  an  adenoma
and  FNH,  MRI  with  injection  of  a  liver-speciﬁc
contrast  agent  can  be  offered  with  analysis  of  the
hepatocyte  phase:  FNH  ‘capture’  the  contrast  agent
while  adenomas  do  not.
• Take  care  with  the  classic  MRI  pitfalls:  liver  overload
can  change  analysis  of  the  behavior  of  a  lesion  in
MRI;  not  all  hypervascular  lesions  are  hepatocellular
lesions;  the  presence  of  a  central  stellate  scar  is  not
synonymous  with  FNH.
• In  contrast  enhanced  ultrasound,  the  presence  of
centripetal  or  mixed  ﬂow  does  not  exclude  diagnosis
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Rof  FNH  for  lesions  larger  than  5-cm.
ame  from  a  female  donor  cadaver.  Given  the  small  size  of
he  nodule  and  its  subcapsular  position,  difﬁcult  to  biopsy,
 multidisciplinary  consultative  meeting  decided  on  close
onitoring.  The  various  monitoring  imaging  examinations
ave  shown  it  remaining  stable  over  a  year.  This  nodule  was
herefore  diagnosed  as  FNH.
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nset 1. Proposition for the management
f  hepatic nodules compatible with benign
epatocellular tumors.
.  Context:  Sex?  Neoplastic  history?  Chronic  liver  disease?
ontraception?  Liver  staging?  Tumor  markers?  Hepati-
is  serology?
2.  Analysis  of  the  overall  liver  signal:  Steatosis?  Iron  over-
oad?
3.  Analysis  of  the  nodule:
Size?  <  3-cm?  >  5-cm?
Presence  of  fat?  Throughout?  Focal?
T2-weighted  signal?
Homogeneous  lesion?L.  Baranes  et  al.
Central  stellate  scar?  T2-weighted  signal?
Arterial  enhancement?
Venous  phase  signal?
nce  this  analysis  is  complete,  several  situations  could  arise.
he  lesion  suggests:.
Typical
FNH
Steatotic
adenoma
Inﬂammatory
adenoma
Other  Non-typical FNH or
diagnosis between
adenoma and FNH difﬁcult
Action to take
STOP Monitoring?
Biopsy?
Biopsy Biopsy Contrast enhanced
ultrasound if
nodule < 5-cm
±
MRI with injection of
liver-speciﬁc contrast
agent with the hepatocyte
phase
Contrast uptake in the
hepatocyte phase
and/or
contrast enhanced
ultrasound suggesting FNH
= FNH
STOP?
Monitoring?
No hepatocyte contrast
uptake
= Not FNH
Biopsy
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